Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
In the latest session, Neogenomics Inc (NASDAQ: NEO) closed at $12.13 down -1.70% from its previous closing price of $12.34. In other words, the price has decreased by -$1.70 from its previous closing price. On the day, 1.98 million shares were traded. NEO stock price reached its highest trading level at $12.4 during the session, while it also had its lowest trading level at $12.09.
Ratios:
For a deeper understanding of Neogenomics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.62 and its Current Ratio is at 3.91. In the meantime, Its Debt-to-Equity ratio is 0.49 whereas as Long-Term Debt/Eq ratio is at 0.48.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 25 ’25 when ALICIA OLIVO bought 11,939 shares for $11.61 per share.
ALICIA OLIVO bought 4,918 shares of NEO for $49,032 on Oct 16 ’25. On Aug 06 ’25, another insider, Sherman Jeffrey Scott, who serves as the Chief Financial Officer of the company, bought 20,000 shares for $5.62 each. As a result, the insider paid 112,322 and bolstered with 188,332 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NEO now has a Market Capitalization of 1569474048 and an Enterprise Value of 1815665024. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.21 while its Price-to-Book (P/B) ratio in mrq is 1.86. Its current Enterprise Value per Revenue stands at 2.56 whereas that against EBITDA is -527.35.
Stock Price History:
The Beta on a monthly basis for NEO is 1.55, which has changed by -0.31584883 over the last 52 weeks, in comparison to a change of 0.12934029 over the same period for the S&P500. Over the past 52 weeks, NEO has reached a high of $19.11, while it has fallen to a 52-week low of $4.72. The 50-Day Moving Average of the stock is 24.45%, while the 200-Day Moving Average is calculated to be 41.69%.
Shares Statistics:
For the past three months, NEO has traded an average of 3.54M shares per day and 2200080 over the past ten days. A total of 128.89M shares are outstanding, with a floating share count of 123.00M. Insiders hold about 4.94% of the company’s shares, while institutions hold 96.69% stake in the company. Shares short for NEO as of 1763078400 were 8416654 with a Short Ratio of 2.38, compared to 1760486400 on 6508598. Therefore, it implies a Short% of Shares Outstanding of 8416654 and a Short% of Float of 8.959999999999999.
Earnings Estimates
A comprehensive evaluation of Neogenomics Inc (NEO) is underway, with the input of 13.0 analysts contributing to its current rating.The consensus estimate for the next quarter is $0.02, with high estimates of $0.06 and low estimates of -$0.04.
Analysts are recommending an EPS of between $0.12 and $0.08 for the fiscal current year, implying an average EPS of $0.1. EPS for the following year is $0.18, with 13.0 analysts recommending between $0.3 and $0.06.
Revenue Estimates
A total of 13 analysts believe the company’s revenue will be $188.4M this quarter.It ranges from a high estimate of $193M to a low estimate of $186.6M. As of. The current estimate, Neogenomics Inc’s year-ago sales were $172MFor the next quarter, 13 analysts are estimating revenue of $187.98M. There is a high estimate of $194.32M for the next quarter, whereas the lowest estimate is $183M.
A total of 14 analysts have provided revenue estimates for NEO’s current fiscal year. The highest revenue estimate was $730.2M, while the lowest revenue estimate was $723.7M, resulting in an average revenue estimate of $725.56M. In the same quarter a year ago, actual revenue was $660.57MBased on 14 analysts’ estimates, the company’s revenue will be $797.57M in the next fiscal year. The high estimate is $807.13M and the low estimate is $784.8M.
